Biodesix Inc CEO Scott Hutton Sells 64,390 Shares
On February 12, 2024, Scott Hutton, President & CEO of Biodesix Inc (NASDAQ:BDSX), sold 64,390 shares of the company's stock, according to a recent SEC Filing. The transaction was executed with the shares priced at $1.8 each, resulting in a total sale amount of $115,902.
Biodesix Inc is a data-driven diagnostic solutions company with a focus on lung disease. The company leverages its proprietary diagnostic platform to develop testing solutions that assist physicians in diagnosing and treating lung diseases. Biodesix's goal is to provide patients with information that can guide treatment decisions and improve patient outcomes.
Over the past year, the insider has sold a total of 95,719 shares and has not made any share purchases. This latest transaction continues a pattern of insider sales for the company.
The insider transaction history for Biodesix Inc shows a trend of more insider sales than purchases over the past year, with 6 insider buys and 20 insider sells recorded.
On the valuation front, Biodesix Inc's shares were trading at $1.8 on the day of the insider's recent sale, giving the company a market capitalization of $149.286 million. The stock's price-to-GF-Value ratio stands at 1.41, indicating that the stock is modestly overvalued when compared to the GuruFocus Value of $1.28.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
